DE69525151T2 - Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat - Google Patents

Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat

Info

Publication number
DE69525151T2
DE69525151T2 DE69525151T DE69525151T DE69525151T2 DE 69525151 T2 DE69525151 T2 DE 69525151T2 DE 69525151 T DE69525151 T DE 69525151T DE 69525151 T DE69525151 T DE 69525151T DE 69525151 T2 DE69525151 T2 DE 69525151T2
Authority
DE
Germany
Prior art keywords
cells
sertoli cells
xenotransplantat
allotransplant
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69525151T
Other languages
English (en)
Other versions
DE69525151D1 (de
Inventor
P Selawry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Corp Technologies Inc
Original Assignee
Research Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Corp Technologies Inc filed Critical Research Corp Technologies Inc
Publication of DE69525151D1 publication Critical patent/DE69525151D1/de
Application granted granted Critical
Publication of DE69525151T2 publication Critical patent/DE69525151T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0683—Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0677—Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/24—Genital tract cells, non-germinal cells from gonads
    • C12N2502/246—Cells of the male genital tract, non-germinal testis cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
DE69525151T 1994-04-13 1995-04-13 Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat Expired - Lifetime DE69525151T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21169594A 1994-04-13 1994-04-13
PCT/US1995/004565 WO1995028167A1 (en) 1994-04-13 1995-04-13 Methods of treating disease using sertoli cells and allografts or xenografts

Publications (2)

Publication Number Publication Date
DE69525151D1 DE69525151D1 (de) 2002-03-14
DE69525151T2 true DE69525151T2 (de) 2002-08-14

Family

ID=22787974

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69525151T Expired - Lifetime DE69525151T2 (de) 1994-04-13 1995-04-13 Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat

Country Status (12)

Country Link
US (3) US5725854A (de)
EP (1) EP0755258B1 (de)
JP (1) JPH09512015A (de)
AT (1) ATE212230T1 (de)
AU (1) AU715177B2 (de)
CA (1) CA2187803C (de)
DE (1) DE69525151T2 (de)
DK (1) DK0755258T3 (de)
ES (1) ES2169128T3 (de)
FI (2) FI120670B (de)
NO (1) NO320713B1 (de)
WO (1) WO1995028167A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293718B6 (cs) * 1995-02-08 2004-07-14 Yamanouchi Europe B. V. Způsob přípravy granulátu obsahujícího orálně účinné beta-laktamové antibiotikum a orální dávkovací forma obsahující orálně účinné beta-laktamové antibiotikum
US5702700A (en) * 1995-03-13 1997-12-30 University Of South Florida Sertoli cells as neurorecovery inducing cells for Parkinson's disease
US5830460A (en) 1995-03-13 1998-11-03 University Of South Florida Sertoli cells as transplantation facilitator for cell transplantation
EP0814819B1 (de) * 1995-03-13 2004-07-14 University Of South Florida Sertolizellen als transplantationunterstützer bei zelltransplantationen
AU5390696A (en) * 1995-04-20 1996-11-07 University Of South Florida Purified and isolated sertoli cell aggregate
US6037175A (en) * 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
AU759273B2 (en) * 1998-01-02 2003-04-10 Titan Pharmaceuticals, Inc. Use of retinal pigment epithelial cells for creation of an immune privilege site
CA2349475C (en) * 1998-11-06 2010-01-05 Shaun A. Kirkpatrick Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells
US7399751B2 (en) * 1999-11-04 2008-07-15 Sertoli Technologies, Inc. Production of a biological factor and creation of an immunologically privileged environment using genetically altered Sertoli cells
HU226054B1 (en) * 1998-12-15 2008-04-28 Univ Mexico Nacional Autonoma Process and device for facilitating the implantation of biological material
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US7115256B1 (en) 1999-04-09 2006-10-03 Titan Pharmaceuticals, Inc. Methods of treating schizophrenia
US7122177B2 (en) 2000-01-20 2006-10-17 Diabcell Pty Ltd. Preparation and xenotransplantation of porcine islets
US6790441B1 (en) 2000-06-13 2004-09-14 University Of South Florida Sertoli cells as biochambers
CA2421036A1 (en) 2000-09-20 2002-03-28 Islet Sheet Medical Llc Fabrication of thin sheet bio-artificial organs
BRPI0209552B1 (pt) 2001-05-11 2016-05-10 Johnson & Johnson dispositivo de modulação de imunidade e método para fabrica-lo
EP1438395B1 (de) * 2001-09-28 2011-11-30 Diabcell Pty Limited Züchtung von fremdtransplantationsmaterial in kultur
WO2003070275A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040062753A1 (en) * 2002-09-27 2004-04-01 Alireza Rezania Composite scaffolds seeded with mammalian cells
CA2529573A1 (en) * 2003-06-24 2004-12-29 Diabcell Pty Limited Porcine islets cultured with porcine sertoli cells for xenotransplantation
EP1648380B1 (de) * 2003-07-03 2015-04-08 Sertoli Technologies, LLC Zusammensetzungen mit sertoli-zellen und myoid-zellen und ihre verwendung in zellulären transplanten
US8263068B2 (en) * 2004-04-29 2012-09-11 Washington State University Research Foundation Modified cells expressing a protein that modulates activity of bHLH proteins, and uses thereof
US7910359B2 (en) 2004-07-29 2011-03-22 University Of Miami Hybrid device for cell therapies
US20070065422A1 (en) * 2005-09-20 2007-03-22 Cameron Don F Induction of immune tolerance by sertoli cells
US20090028833A1 (en) * 2006-01-26 2009-01-29 John Constance M Proliferative Primary Human Sertoli Cell Cultures And Their Applications
JP2010500871A (ja) * 2006-07-28 2010-01-14 セルトセル・バイオテクノロジー・（ユーエス）・コーポレイション 成熟セルトリ細胞およびその使用
US9161901B2 (en) 2008-02-21 2015-10-20 University Of South Florida Nanoparticle targeted drug delivery to the lungs using extra-testicular Sertoli cells
US8709400B2 (en) * 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
PL3290061T3 (pl) 2009-08-28 2020-11-02 Sernova Corporation Sposoby i urządzenia do przeszczepiania komórek
MX2010013135A (es) 2010-11-30 2012-05-31 Val De Bio S De R L De C V Procedimiento y dispositivo mejorados para favorecer el trasplante de material biológico.
US10532128B2 (en) 2015-11-18 2020-01-14 Viera Bioscience, Inc. Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction
WO2019079384A1 (en) 2017-10-17 2019-04-25 The Methodist Hospital System ADMINISTRATION DEVICES
WO2020223670A1 (en) 2019-05-01 2020-11-05 Sernova Corporation Methods of treating diabetes using devices for cellular transplantation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158874A (en) * 1985-08-30 1992-10-27 The United States Of America As Represented By The Department Of Health And Human Services Determining metastic potential of tumor cells and isolating metastic tumor cells
US4829000A (en) * 1985-08-30 1989-05-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Reconstituted basement membrane complex with biological activity
US5053332A (en) * 1989-07-24 1991-10-01 Cook Richard B Agarose beads, preferably incorporating biological materials
US5304603A (en) * 1991-06-18 1994-04-19 The Population Council Leydig cell stimulator
DE4227066A1 (de) * 1992-08-16 1994-02-17 Bernhard Josef Dr Med Hering Langerhans'sche Inseln in reiner Form
US5474905A (en) * 1993-11-24 1995-12-12 Research Corporation Technologies Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells

Also Published As

Publication number Publication date
JPH09512015A (ja) 1997-12-02
FI964033A0 (fi) 1996-10-08
AU2289395A (en) 1995-11-10
NO964342D0 (no) 1996-10-11
DE69525151D1 (de) 2002-03-14
WO1995028167A1 (en) 1995-10-26
AU715177B2 (en) 2000-01-20
FI120696B (fi) 2010-01-29
FI964033A (fi) 1996-12-12
NO964342L (no) 1996-12-13
FI120670B (fi) 2010-01-29
EP0755258A1 (de) 1997-01-29
US5843430A (en) 1998-12-01
ES2169128T3 (es) 2002-07-01
FI20085733A (fi) 2008-07-18
ATE212230T1 (de) 2002-02-15
EP0755258B1 (de) 2002-01-23
CA2187803A1 (en) 1995-10-26
NO320713B1 (no) 2006-01-23
US5725854A (en) 1998-03-10
US5759534A (en) 1998-06-02
CA2187803C (en) 1999-09-28
DK0755258T3 (da) 2002-05-13

Similar Documents

Publication Publication Date Title
DE69525151T2 (de) Methoden zur krankheitsbehandlung unter verwendung von sertoli-zellen und allotransplantat oder xenotransplantat
ATE220929T1 (de) Behandlung von biologischen materialen vor der fixierung
DE60045034D1 (de) Überstände von mesenchymstammzellen zur vorbeugung und behandlung von immunantworten in transplantationen
BR9710689A (pt) Processo para tratar diarr-ia aguda e para proporcionar terapia a um mam¡fero tendo diarr-ia e prepara-Æo terap-utica para redu-Æo de sintomas de diarr-ia
DK0702563T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer og hyperproliferative sygdomme
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
ID30237A (id) KOMBINASI PENGHAMBAT-PENGHAMBAT FBPase DAN PEMEKA-PEMEKA INSULIN UNTUK PENGOBATAN DIABETES
DE69635924D1 (de) Isolierung und züchtung von schwannzellen
ATE248592T1 (de) Verwendung von naaladase hemmern zur herstellung eines medikaments zur behandlung von bestimmten krankheiten
EA200100195A1 (ru) Ингибирование реакции "трансплантат против хозяина"
EA199700241A1 (ru) Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран
DE60039160D1 (de) Verwendung von erbb-rezeptorliganden zur behandlung von diabetes
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
BR0213429A (pt) Métodos para regenerar a função do pâncreas em um indivìduo, para tratar o diabete em um paciente humano e para produzir célula pancreática funcional de animal, célula pancreática funcional de animal, uso da mesma, e, método para roduzir célula pancreática de animal em diferentes estágios de desenvolvimento
TW200507875A (en) Remedy for diabetes
ATE264112T1 (de) Verwendung von il-7 zur behandlung von autoimmunkrankheiten, insbesondere insulinabhängigem diabetes mellitus
WO2004030628A3 (en) Adult bone marrow derived stem cells
NO20012214L (no) Fremstilling av en biologisk faktor og frembringelse av et immunologisk fordelaktig miljö ved anvendelse av genetiskforandrede Sertoliceller
DE69001240D1 (de) Methoden zur verwendung von 2-isopropyl-2-phenylaminovaleriansaeurenitrilen als immunosupressoren und vasodilatoren.
GEP19970991B (en) Method for Decay of Tumor Cells with Mammalia and Pharmacentical Composition for this Purpose
UA10281C2 (uk) Спосіб отримання речовини для лікування захворювань підшлункової залози
UA3561U (uk) Спосіб лікування діабетичної ретинопатії

Legal Events

Date Code Title Description
8364 No opposition during term of opposition